PMP22 and Charcot-Marie-Tooth disease type 1A: Preclinical in vivo studies on C22 mice demonstrated that ascorbic acid reduced the expression of PMP22, a key protein implicated in CMT1A pathogenesis, and improved motor function [16,17].